In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

Kennedy Jr. earned more than $2.4 million as a consultant referring cases to the law firm Wisner Baum, government records show. Wisner Baum is suing Merck & Co. over allegations that the ...

Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a White contractor from a project, a New York federal judge ruled.

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $98.28 which represents a slight increase of $0.83 or 0.85% from the prior close of $97.45. The stock opened at $97.42 and touched a ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

A significant insider buy by Jennifer Zachary, EVP at Merck & Co MRK , was executed on January 29, and reported in the recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.